1795 Stock Overview
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Lotus Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$285.50 |
| 52 Week High | NT$347.00 |
| 52 Week Low | NT$210.50 |
| Beta | 0.54 |
| 11 Month Change | 10.23% |
| 3 Month Change | 1.42% |
| 1 Year Change | 13.97% |
| 33 Year Change | 153.78% |
| 5 Year Change | 150.44% |
| Change since IPO | 131.17% |
Recent News & Updates
Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 16
Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem
Nov 14Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden
Oct 23Recent updates
Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 16Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem
Nov 14Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden
Oct 23Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next
Aug 14Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)
Jul 18Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?
Apr 24Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price
Apr 09Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals
Mar 22These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively
Apr 04Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 09Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?
Feb 11
Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?
Jan 21Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?
Dec 31I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease
Dec 10Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next
Nov 19Shareholder Returns
| 1795 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 1.2% | 0.6% | -0.8% |
| 1Y | 14.0% | 9.2% | 29.0% |
Return vs Industry: 1795 exceeded the TW Pharmaceuticals industry which returned 9.2% over the past year.
Return vs Market: 1795 underperformed the TW Market which returned 29% over the past year.
Price Volatility
| 1795 volatility | |
|---|---|
| 1795 Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 1795 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1795's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1966 | n/a | Petar Vazharov | www.lotuspharm.com.tw |
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system diseases. The company also provides over-the-counter products.
Lotus Pharmaceutical Co., Ltd. Fundamentals Summary
| 1795 fundamental statistics | |
|---|---|
| Market cap | NT$75.71b |
| Earnings (TTM) | NT$4.33b |
| Revenue (TTM) | NT$17.59b |
17.5x
P/E Ratio4.3x
P/S RatioIs 1795 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1795 income statement (TTM) | |
|---|---|
| Revenue | NT$17.59b |
| Cost of Revenue | NT$7.67b |
| Gross Profit | NT$9.92b |
| Other Expenses | NT$5.59b |
| Earnings | NT$4.33b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 16.34 |
| Gross Margin | 56.39% |
| Net Profit Margin | 24.63% |
| Debt/Equity Ratio | 60.0% |
How did 1795 perform over the long term?
See historical performance and comparison